TE Maione et al (1991) Cancer Research 51: 2077-2083. |
N Sakamoto et al (1991) Cancer Research 51: 903-906. |
MS Sheikh et al (1995) Oncogene 11: 1899-1905. |
TPD Fan et al (1995) Trends Pharmaceutical Sciences 16:57-66. |
I Saiki et al (1990) Japanese J Cancer Research 81:668-675. |
C Clapp et al (1993) Endocrinology 133: 1292-1299. |
MJ Hawkins (1995) Current Opinion in Oncology 7:90-93. |
Human Gene Therapy, 6:395-405 (Apr. 1995), "Systemic Gene Therapy with p53 Reduces Growth & Metastases of a Malignant Human Breast Cancer in Nude Mice" Leslie A. Lesoon-Wood et al. |
Human gene Therapy 8:177-185 (Jan. 20, 1997), "Parenteral gene Therapy with p53 Inhibits Human Breast Tumors In Vivo Through a Bystander Mechanism Without Evidence of Toxicity", M. Xu et al. |
Molecular Genetics & Metabolisms 63-103-109 (1998), "Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breast Cancer in Vivo", M. Xu et al. |
Molecular genetics & Metabolism 64,000-000 (1998), "In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes" M. Xu et al. |
Lesoon-Wood et a., Human Gene Therapy, 6:395-405 (Apr. 1995), pp. 395-405. |
Weinstat-Saslow et al., Cancer Research 54:6504-6511 (1994). |
Dameron et al., Science. vol. 265;1582 (1994). |
O'Reilly et al., Cell, vol. 79:315, (1994). |
Millauer et al., Nature, vol. 367:576, (1994). |
Pasquallni et al., Nature, vol. 380:364, (1996). |
Tanaka et al., Nature Medicine, vol. 3:437 (1997). |
"Vectors for Gene Therapy", Chapter 12, John Wiley and Sons (1997). |
O'Reilly et al., Cell, 88:277, (1997). |
Calos, TIG, vol. 12:463, (1996). |
Tolsma et al., The Journal of Cell Biology, vol. 122, Jul. 1993, pp. 497-510. |
Goldman et al., Nature Biotechnology, 15:462, (1997). |
Boussif et al., Proc. Natl. Acad. Sci., vol. 92: 7297, (1995). |
Cheng, Human Gene Therapy, 7:275, (1996). |
Pasqulini et al., Nature Biotechnology, 15:542, (1997). |
Park et al., Proc. Am. Ass. Canc. Res., 38, No. 2291, (Mar. 1997). |